Experimental ex vivo studies on monocytes collected from RA patients when treated with recombinant human soluble IL-7Rα in vitro inhibited IL-7-induced T-cell proliferation and interferon-γ (IFN-γ) production, suggesting that IL-7Rα blockade might of potential importance as an alternative strategy to TNF-α blockade for limiting IL-7-induced RA immunopathology. Here, IL7 is linked to rheumatoid arthritis.